SC 13D/A

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

(Rule 13d-102)

INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a)

AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

(Amendment No. 1)*

MILESTONE SCIENTIFIC INC.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

59935P100

(CUSIP Number)

Innovest S.p.A.

Corso Venezia 44

Milan, Italy 20121

Tel: +39 02 231 64798 Fax: +39 02 231 61949

Copy to:

Ettore A. Santucci, Esq.

Goodwin Procter LLP

Exchange Place

53 State Street

Boston, Massachusetts 02109

Tel: (617) 570-1000 Fax: (617) 523-1231

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 29, 2016

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.    ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.l3d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 59935P100 13D/A Page 2 of 12 Pages

1.	NAMES OF REPORTING PERSONS BP4 S.r.l.
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)  ¨    (b)   x
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (SEE INSTRUCTIONS) WC
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Italy
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER 5,750,491
		8.	SHARED VOTING POWER 0
		9.	SOLE DISPOSITIVE POWER 5,750,491
		10.	HARED DISPOSITIVE POWER 0
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,750,491
12.	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 23.5%
14.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

CUSIP No. 59935P100 13D/A Page 3 of 12 Pages

1.	NAMES OF REPORTING PERSONS Innovest S.p.A.
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)  ¨    (b)   x
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (SEE INSTRUCTIONS) AF
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Italy
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER 5,750,491
		8.	SHARED VOTING POWER 0
		9.	SOLE DISPOSITIVE POWER 5,750,491
		10.	SHARED DISPOSITIVE POWER 0
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,750,491
12.	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 23.5%
14.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

CUSIP No. 59935P100 13D/A Page 4 of 12 Pages

1.	NAMES OF REPORTING PERSONS Giandomenico Trombetta
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)  ¨    (b)   x
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (SEE INSTRUCTIONS) AF
5.	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION Italy
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER 5,861,141 (1)
		8.	SHARED VOTING POWER 0
		9.	SOLE DISPOSITIVE POWER 5,861,141 (1)
		10.	SHARED DISPOSITIVE POWER 0
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,861,141
12.	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 24.0%
14.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

(1) This number includes options to purchase 44,260 shares exercisable within 60 days of June 29, 2016.

CUSIP No. 59935P100 13D/A Page 5 of 12 Pages

ITEM 1. SECURITY AND ISSUER.

This Statement on Schedule 13D relates to shares of common stock, $0.001 par value (the “Common Stock”), including shares of Common Stock issuable upon conversion of shares of Series A Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”) (together, the “Shares”) of Milestone Scientific Inc., a Delaware corporation (the “Issuer”). The address of the Issuer’s principal executive office is 220 S. Orange Avenue, Livingston, New Jersey 07039.

ITEM 2. IDENTITY AND BACKGROUND.

Item 2 (a) — (c). This statement is being filed by the following persons:

(i) BP4 S.r.l. (“BP4”), an Italian Società a Responsabilità Limitata;

(ii) Innovest S.p.A. (“Innovest”), an Italian Società per Azioni specialized in private equity and distressed equity investments, and the controlling shareholder of BP4; and

(iii) Mr. Giandomenico Trombetta, a shareholder and director of each of BP4 and Innovest.

Each of BP4, Innovest and Mr. Trombetta is sometimes referred to herein as a “Reporting Person” and together, as the “Reporting Persons.”

Each of BP4 and Innovest is principally engaged in the business of investing in securities. The principal occupation of Mr. Trombetta is serving as a director and officer of Innovest and its affiliates, including BP4.

Set forth on Schedule A attached hereto is the name, present principal occupation or employment (and the name, principal business and address of any corporation or other organization in which such employment is conducted) and the citizenship of each of the directors and executive officers of BP4 and Innovest as of the date hereof.

The business address and principal executive offices of each of BP4 and Innovest, and their executive officers and directors are c/o Innovest S.p.A., Corso Venezia 44, Milan, Italy 20121.

Item 2 (d) — (e). During the last five years, none of the persons identified in this Item 2 has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors), or has been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.

Item 2 (f). Each natural person identified in this Item 2 is a citizen of Italy.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

BP4 used its own assets to purchase the Shares directly owned by BP4. The aggregate amount of funds used to purchase the 3,000,000 shares of Common Stock and 7,000 shares of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”), was $12,000,000.

ITEM 4. PURPOSE OF TRANSACTION.

On May 14, 2014, BP4 acquired 2,000,000 shares of Common Stock and 7,000 shares of Series A Preferred Stock from the Issuer in a private placement pursuant to an Investment Agreement, dated April 15, 2014, between BP4 and the Issuer (the “Investment Agreement”). Pursuant to the Investment Agreement, the Reporting Person has the right to elect one person to the Issuer’s Board of Directors.

On February 4, 2016, Issuer granted 66,390 shares of Common Stock and options to purchase 132,780 shares of Common Stock, 44,260 shares of which are exercisable within 60 days of the date hereof, to Mr. Giandomenico Trombetta.

CUSIP No. 59935P100 13D/A Page 6 of 12 Pages

On June 29, 2016, BP4 acquired 1,000,000 shares of Common Stock from the Issuer in a private placement pursuant to a letter agreement, dated June 16, 2016, between BP4 and the Issuer (the “Letter Agreement”). The payment was made in two tranches. The first payment was made on June 17, 2016 whereas the final payment was made on June 22, 2016. The shares were issued on June 29, 2016.

BP4 acquired the shares held by it for investment purposes. The Reporting Persons also intend to participate in and influence the affairs of the Issuer through exercise of their rights to nominate a director to the Issuer’s Board of Directors pursuant to the Investment Agreement and through their voting rights with respect to all of their Shares. Mr. Trombetta currently serves as the representative of the Reporting Persons on the Issuer’s Board of Directors, and also as the President and Chief Executive Officer of the Issuer’s dental division.

Although no Reporting Person currently has any specific plan or proposal to acquire or dispose of any Common Stock or any securities exercisable for or convertible into Common Stock, each Reporting Person, consistent with its investment purpose, at any time and from time to time may directly or indirectly acquire additional Common Stock or associated rights or securities exercisable for or convertible into Common Stock or dispose of any or all of its Common Stock or its associated rights or securities exercisable for or convertible into Common Stock depending upon an ongoing evaluation of its investment in such securities, applicable legal and/or contractual restrictions, prevailing market conditions, other investment opportunities, liquidity requirements of such Reporting Person and/or other investment considerations.

In addition, BP4, solely in its capacity as a stockholder of the Issuer, Innovest, in its capacity as controlling shareholder of BP4, and Mr. Trombetta, as a director and shareholder of each of BP4 and Innovest, may engage in communications with one or more other shareholders of the Issuer, one or more officers of the Issuer and/or one or more members of the Board of Directors of the Issuer and/or one or more representatives of the Issuer with respect to matters relating to the Issuer, including but not limited to its operations. Each of the Reporting Persons, in such capacities, may discuss ideas that, if effected, may relate to, or may result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D.

Other than as described above and any plans or proposals that may from time to time be discussed or considered by the board of directors of the Issuer, including Mr. Trombetta, in their fiduciary capacities as directors, each of the Reporting Persons reports that neither it nor, to its knowledge, any of the other persons named in Item 2 of this Schedule 13D, currently has any plan or proposal which relates to, or may result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although the Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

(a)-(b)

BP4 beneficially owns and has sole voting and dispositive power with respect to 3,000,000 shares of Common Stock and 7,000 shares of Series A Preferred Stock, convertible into 2,750,491 shares of Common Stock, which in the aggregate represent beneficial ownership of 23.5% of the total outstanding Common Stock of the Issuer.

Innovest, through its control of BP4, beneficially owns and has sole voting and dispositive power with respect to all 3,000,000 shares of Common Stock and 7,000 shares of Series A Preferred Stock directly owned by BP4.

Mr. Trombetta, through his control of Innovest, beneficially owns and has sole voting and dispositive power with respect to all 3,000,000 shares of Common Stock and 7,000 shares of Series A Preferred Stock directly owned by BP4. Mr. Trombetta also directly owns 66,390 shares of Common Stock and options to purchase 132,780 shares of Common Stock, 44,260 shares of which are exercisable within 60 days of the date hereof. In the aggregate, Mr. Trombetta has a beneficial ownership of 24.0% of the total outstanding Common Stock of the Issuer.

The percentage beneficial ownership of the Reporting Persons described above is calculated based upon (i) the 21,687,164 shares of Common Stock outstanding as of May 16, 2016, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on May 16, 2016, and (ii) in accordance with Rule 13d-3 under the Act, assuming the conversion of the 7,000 shares of Series A Preferred Stock into 2,750,491 shares of Common Stock for the Reporting Persons only.

CUSIP No. 59935P100 13D/A Page 7 of 12 Pages

The Series A Preferred Stock is initially convertible into Common Stock at $2.545 per share and, if not earlier converted, is mandatorily convertible into Common Stock at the end of five years at $2.545 per share, or $1.50 per share if certain conditions have not been met, with such conversion prices subject to anti-dilution adjustments. The Preferred Stock participates in dividends on an as-converted basis only when, as and if declared on the underlying Common Stock.

Except as indicated in this Item 5 or as set forth below, the Reporting Person does not own beneficially, or have any right to acquire, directly or indirectly, any shares of Common Stock.

(c) Except as set forth herein, none of the Reporting Persons has effected any transaction during the past 60 days in any shares of Common Stock.

(d) Except as set forth herein, to the knowledge of the Reporting Persons, no person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities covered by this Schedule 13D.

Item 5 (e). Not Applicable.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

Stock Purchase Agreement

The Issuer entered into the Investment Agreement with the Reporting Person, pursuant to which the Reporting Person acquired (a) 2,000,000 shares of Common Stock and (b) the shares of Series A Preferred Stock that are convertible, at the option of the Reporting Person, into shares of Common Stock. The foregoing description of the Investment Agreement is intended as a summary only and is qualified in its entirety by reference to the Investment Agreement, which is filed as Exhibit A to this Schedule 13D and incorporated by reference herein.

Registration Rights Agreement

In connection with the closing of the transactions contemplated by the Investment Agreement, the Issuer entered into a Registration Rights Agreement, dated as of May 14, 2014 (the “Registration Rights Agreement”), with the Reporting Person, pursuant to which the Issuer granted registration rights to the Reporting Person with regard to the Common Stock held by each Investor. Under the Registration Rights Agreement, BP4 has certain limited demand registration rights and piggyback rights, subject to customary underwriter cutbacks and issuer blackout periods. The Reporting Person will pay all fees and expenses relating to the registration of the Common Stock pursuant to the Registration Rights Agreement. The foregoing description of the Registration Rights Agreement is intended as a summary only and is qualified in its entirety by reference to the Registration Rights Agreement, which is filed as Exhibit B to this Schedule 13D and incorporated by reference herein.

Certificate of Designation

The Issuer filed a Certificate of Designation with the Secretary of State of the State of Delaware on May 14, 2014 that, among other things, sets forth the preferential and protective provisions of the Series A Preferred Stock. The foregoing description of the terms of the Certificate of Designation is intended as a summary only and is qualified in its entirety by reference to the Certificate of Designation, which is filed as Exhibit C to this Schedule 13D and incorporated by reference herein.

Letter Agreement

The Issuer entered into the Letter Agreement with the Reporting Person, pursuant to which the Reporting Person acquired 1,000,000 shares of Common Stock. The foregoing description of the Letter Agreement is intended as a summary only and is qualified in its entirety by reference to the Letter Agreement, which is filed as Exhibit D to this Schedule 13D and incorporated by reference herein.

CUSIP No. 59935P100 13D/A Page 8 of 12 Pages

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Exhibit	Description
A	Investment Agreement, dated as of April 15, 2014, between Milestone Scientific Inc. and BP4 S.r.l. (filed as Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed on April 18, 2014).
B	Registration Rights Agreement, dated as of May 14, 2014, by and among Milestone Scientific Inc. and BP4 S.r.l. (filed as Exhibit B to the Schedule 13D filed on May 27, 2014)
C	Milestone Scientific Inc. Form of Certificate of Designation of Series A Preferred Stock (filed as Exhibit 10.2 to the Issuer’s Current Report on Form 8-K filed on April 18, 2014).
D	Letter Agreement, dated as of June 16, 2016, between Milestone Scientific Inc. and BP4 S.r.l.

CUSIP No. 59935P100 13D/A Page 9 of 12 Pages

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

Dated: June 30, 2016

BP4 S.r.l.
By:	/s/ Giandomenico Trombetta
	Name: Giandomenico Trombetta Title: Director

Innovest S.p.A.
By:	/s/ Giandomenico Trombetta
	Name: Giandomenico Trombetta Title: Director

Giandomenico Trombetta
By:	/s/ Giandomenico Trombetta
	Giandomenico Trombetta

CUSIP No. 59935P100 13D/A Page 10 of 12 Pages

Schedule A

The name, business address, present principal occupation or employment and citizenship of each of the executive officers and directors of BP4 S.r.l. (“BP4”) are set forth below. Each such person has no other principal occupation (outside of similar positions held with respect to other entities directly or indirectly managed or advised by BP4).

Name	Present Principal Occupation or Employment with BP4	Address of Organization in which Employed	Citizenship
Giandomenico Trombetta	Director, Chief Executive Officer	Corso Venezia 44, Milan, Italy 20121	Italy

CUSIP No. 59935P100 13D/A Page 11 of 12 Pages

The name, business address, present principal occupation or employment and citizenship of each of the executive officers and directors of Innovest S.p.A. (“Innovest”) are set forth below. Each such person has no other principal occupation (outside of similar positions held with respect to other entities directly or indirectly managed or advised by Innovest).

Name	Present Principal Occupation or Employment with Innovest	Address of Organization in which Employed	Citizenship
Giandomenico Trombetta	Director, Chief Executive Officer	Corso Venezia 44, Milan, Italy 20121	Italy

CUSIP No. 59935P100 13D/A Page 12 of 12 Pages

Joint Filing Agreement

In accordance with Rule 13d-1(f) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Shares of the Issuer and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of June 30, 2016.

BP4 S.r.l.
By:	/s/ Giandomenico Trombetta
	Name: Giandomenico Trombetta Title: Director

Innovest S.p.A.
By:	/s/ Giandomenico Trombetta
	Name: Giandomenico Trombetta Title: Director

Giandomenico Trombetta
By:	/s/ Giandomenico Trombetta
	Giandomenico Trombetta

EX-99.D

Exhibit D

Milestone Scientific Inc.

220 South Orange Avenue

Livingston, New Jersey 07039

Tel: (973) 535-2717

Fax: (973) 535-2829

June 15, 2016

Via e-mail and Regular Mail

gdtrombetta@milestonescientific.com

BP4 S.p.A

c/o Innovest S.p.A.

Corso Venezia 44

Milan, Italy

Re: Milestone Scientific Inc. (“Milestone”)

Dear Sirs:

This will confirm that Milestone has agreed to sell to you and you have agreed to purchase 1,000,000 shares of common stock at $2.00 per share or an aggregate of $2,000,000. Payment will be made directly to Milestone by wire transfer at the account specified on the attachment to this letter in the amount of $1,500,000 on June 17, 2016 and $500,000 within 10 days thereafter. Milestone acknowledges and agrees that the shares of common stock to be sold hereunder will have all of the rights, preferences and privileges of the common stock sold to BP4 S.p.A. under that Investment Agreement dated April 15, 2014 and the related Registration Rights Agreement.

Milestone hereby represents and warrants to you as follows:

(a)     Milestone is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware with all requisite corporate power and corporate authority to execute and deliver this agreement and perform its obligations hereunder, to own its properties and to carry on its business as now conducted.

(b)     On the date hereof, the authorized capital stock of Milestone consists of 50,000,000 shares of its Common Stock and 5,000,000 shares of preferred stock. On March 31, 2016 (i) 21,687,164 shares of Common Stock (excluding the 33,333 shares held in treasury) and 7,000 shares of Series A Convertible Preferred Stock par value $.001, were outstanding, (ii) 1,100,405 shares are reserved to be issued on retirement of certain officers and (iii) options and warrants to purchase up to 1,776,667 shares of Common Stock were outstanding. Except as set forth above there are no shares of Common Stock or any other equity security of Milestone issuable upon conversion, exchange or exercise of any security and Milestone is not contractually obligated to purchase, redeem or otherwise acquire any of its outstanding shares. No stockholder of Milestone is entitled to any preemptive or similar rights to subscribe for the shares you are agreeing to purchase and to Milestone’s knowledge, there are no stockholder, voting or other agreements relating to the rights and obligations of the Company’s stockholders currently in effect other than the Agreement. No bonds, debentures, notes or other indebtedness having the right to vote on any matters on which the stockholders of the Company may vote are issued and outstanding. All shares have been duly and validly issued and are fully paid and non-assessable, and were issued in compliance with the Securities Act and any relevant state securities laws.

(c) The execution and delivery of this agreement and the performance by Milestone of its obligations hereunder (i) have been duly authorized by the Board of Directors of Milestone, and no other corporate or stockholder action is necessary to authorize them, (ii) do not, and will not conflict with, or result in a violation of, any provision of any law, ordinance, permit, concession, grant, franchise, statute, rule or regulation or any judgment, ruling, order, writ, injunction or decree applicable to Milestone or any of its subsidiaries, properties or assets, (iii) do not and will not conflict with or result in a violation of any provision of Milestone’s charter or by-laws, (iv) conflict with, result in a violation or breach of, constitute (with or without due notice or lapse of time or both) a default (or give rise to any right of termination, cancellation or acceleration) under any agreement to which Milestone or any of its subsidiaries is a party, or result in the creation of any lien on or claim against any property or asset of Milestone or any of its subsidiaries, (v) will not require any consent, approval, authorization or permit of, or registration or filing with or notification to, any governmental authority. This agreement constitutes the valid and binding obligation of Milestone, enforceable against Milestone in accordance with its terms, and (vi) will not result in the acceleration of the vesting of any outstanding option, warrant, call, commitment, agreement (including employment agreements), conversion right, preemptive right or other right to subscribe for, purchase or otherwise acquire any of the shares of the capital stock of Milestone or any of its subsidiaries or any right in favor of any other person to terminate or cancel any agreement to which Milestone or any of its subsidiaries is a party.

(d) There are no claims for investment banking fees or similar compensation in connection with the transactions contemplated by this agreement based on any arrangement made by or on behalf of Milestone.

Milestone also confirms that at a meeting of the Board of Directors duly called and held on June 16, 2016 the Resolutions set forth on Exhibit A were duly adopted and remain in full force and effect.

By signing this letter, you confirm that (i) you are an “accredited investor” within the meaning of Rule 215 of the Rules and Regulations under the Securities Act, (ii) you have acquired the shares for investment and acknowledge that you or your offeree representative have received all information about Milestone relevant to this transaction and have been given the opportunity to discuss this with management of Milestone and (iii) you are knowledgeable and sophisticated about investments of this kind, or have relied on the advice of your offeree representative who is so knowledgeable the securities cannot be resold or otherwise disposed of until they are registered under the Securities Act and any applicable state securities laws or an exemption from registration is available.

Since the shares, will not be registered at the time of issuance, the certificates representing the shares delivered to you will bear the following legend:

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR ASSIGNED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR IN A TRANSACTION WHICH IS EXEMPT FROM REGISTRATION UNDER THE ACT.

Please acknowledge your agreement and understanding of the above provisions by signing and dating a copy of this letter and returning it to us by facsimile and mail. The shares will be delivered to you promptly after receipt of your acknowledgement.

Very truly yours,
MILESTONE SCIENTIFIC INC.
By:
	Leonard Osser. CEO

Accepted and agreed to
this 16th day of June, 2016
BP4 S.p.A
By:
	Gian Domenico Trombetta. CEO

Wiring Instructions for Milestone Scientific Inc – Domestic

[Intentionally omitted]

EXHIBIT A

RESOLVED, that the Board acknowledges that pursuant to the Share Purchase Agreement and the transactions contemplated thereby, BP4 s.r.l (“BP4”) and its control persons or persons under common control, if any, and any other person that may be deemed the direct or indirect beneficial owner (as such term is used in Rule 16a-1(a)(2) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of securities of the Corporation that are beneficially owned or deemed to be beneficially owned by BP4 in connection with or resulting from any of the transactions contemplated by the Share Purchase Agreement (collectively, the “Deputizing Stockholders”), and Giandomenico Trombetta may be acquiring or deemed to be acquiring, directly or indirectly, beneficial ownership of securities of the Corporation, including without limitation, shares of Common Stock, par value $0.001 per share, of the Corporation (the “Securities”);

RESOLVED, that each of the Deputizing Stockholders has deputized Giandomenico Trombetta (and any successor thereof designated by any of the Deputizing Stockholders) as its representative on the Board, and that as such each of the Deputizing Stockholders intends to rely, to the extent applicable from time to time, on Rule 16b-3 under the Exchange Act;

RESOLVED, that the acquisition or deemed acquisition of the Securities by each of the Deputizing Stockholders and by Giandomenico Trombetta, in each case pursuant to the transactions contemplated by the Share Purchase Agreement, together with any acquisitions or dispositions or deemed acquisitions or deemed dispositions of any Securities resulting from or contemplated by any conversion, exercise, redemption, cancellation or expiration (for or without value), termination, liquidation or extension thereof or relating thereto, dividends or distributions thereon or any adjustments thereto, or otherwise, in each case as contemplated by the Share Purchase Agreement and/or as a result of the operation of any provision of the Certificate of Incorporation of the Corporation, shall be exempt from the provisions of Section 16(b) of the Exchange Act pursuant to Rule 16b-3 promulgated thereunder;